Nuformix plc

Nuformix plc, through its subsidiary Nuformix Technologies Limited, is a pharmaceutical development company based in London, United Kingdom, focused on treating fibrosis and oncology through drug repurposing. Its pipeline includes NXP001, in Phase 1 for oncology supportive care; NXP002, in pre-clinical stage for idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib in the IP generation phase for oncology. The company has a licensing agreement with Oxilio Ltd. for NXP001 in oncology indications.